帕罗西汀联合癸酸氟哌啶醇治疗难治性强迫症临床研究

Paroxetine plus haloperidol decanoate in the treament of refractory obsesive-compulsive disorder

目的探讨帕罗西汀联合癸酸氟哌啶醇治疗难治性强迫症的临床疗效及安全性。方法对33例难治性强迫症患者给予帕罗西汀联合癸酸氟哌啶醇治疗,观察12w。于治疗前及治疗第4w、8w、12w末采用耶鲁-布朗强迫症量表评定强迫症状、社会功能缺陷筛选量表评定社会功能康复状况、副反应量表评定不良反应。结果治疗12w末显效率为63.6%。强迫症量表总分、强迫观念和强迫行为因子分及社会功能缺陷筛选量表总分随着治疗时间的延续均呈持续性下降,治疗8w末均较治疗前有显著性差异(P<0.05),12w末有极显著性差异(P<0.01)。不良反应轻微,经对症处理可缓解或消失。结论帕罗西汀联合癸酸氟哌啶醇治疗难治性强迫症疗效显著,安全性高,依从性好。

Objective To explore the efficacy and safety paroxetine plus haloperidol decanoate in the treatment of refractory obsesive-compulisive disorder（ROCD）. Methods 33 patients with ROCD were treated with paroxetine plus haloperidol decanoate for 12 weeks. Compulsion symptoms were assessed with the Yale-Brown Obsessive Compulsive Scale（Y-BOCS）, social functional rehabilitation with the Social Disability Screening Schedule（SDSS）and adverse effects with the Treatment Emergant Sympton Scale（TESS）before treatment and at the end of the 4^th,8^th,12^th week treatment. Results At the end of the 12^th week,the excellence rate was 63.6%. The Y-BOCS total score,scores of compulsive idea and act and the SDSS total score lowered contniously as treatment time went on and had significant differences at the end of the 8^th week（P〈0.05） and very significant differences at the end of the 12^th week（P〈0.01） from pretreatment. Adverse effects were milder and could relieve or disappear after symptomatic treatment. Conclusion Paroxetine plus haloperidol decanoate has significant effects,higher safety and better compliance in the treatrment of refractory obsesive-compulisive disorder.